NEO-ADJUVANT 177LU-PSMA-I&T RADIONUCLIDE IN HIGH-RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY: A FEASIBILITY TRIAL

被引：0
|
作者：
Frumer, Michael
Rosenbaum, Eli
Kedar, Daniel
Zohar, Yarden
Baniel, Jack
Steinmetz, Adam
Bernstine, Hanna
Groshar, David
Golan, Shay
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP15-20
引用
收藏
页码：E271 / E271
页数：1
相关论文
共 50 条
  • [1] Neo-adjuvant 177Lu-PSMA-I&T radionuclide in high-risk prostate cancer before radical prostatectomy: A feasibility trial
    Frumer, M.
    Rosenbaum, E.
    Kedar, D.
    Zohar, Y.
    Baniel, J.
    Steinmetz, A.
    Bernstine, H.
    Groshar, D.
    Golan, S.
    EUROPEAN UROLOGY, 2021, 79 : S1705 - S1705
  • [2] Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial
    Golan, Shay
    Frumer, Michael
    Zohar, Yarden
    Rosenbaum, Eli
    Yakimov, Maxim
    Kedar, Daniel
    Margel, David
    Baniel, Jack
    Steinmetz, Adam P.
    Groshar, David
    Domachevsky, Liran
    Bernstine, Hanna
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (02): : 151 - 159
  • [3] THE EFFECT OF NEO-ADJUVANT CHEMOTHERAPY ON RADICAL PROSTATECTOMY OUTCOMES IN INTERMEDIATE AND HIGH-RISK PROSTATE CANCER
    Kang, Taejin
    Kim, Wansuk
    Lee, Jungmin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF UROLOGY, 2010, 183 (04): : E230 - E231
  • [4] LUTECTOMY: A PHASE I/II TRIAL EVALUATING (177Lu)Lu-PSMA-617 PRIOR TO RADICAL PROSTATECTOMY IN MEN WITH HIGH-RISK LOCALISED PROSTATE CANCER
    Buteau, James
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 65 - 65
  • [5] A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies
    Joshua R. Gonzalez
    Melissa A. Laudano
    Tara R. McCann
    James M. McKiernan
    Mitchell C. Benson
    World Journal of Urology, 2008, 26 : 475 - 480
  • [6] A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies
    Gonzalez, Joshua R.
    Laudano, Melissa A.
    McCann, Tara R.
    McKiernan, James M.
    Benson, Mitchell C.
    WORLD JOURNAL OF UROLOGY, 2008, 26 (05) : 475 - 480
  • [7] 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer:FirstClinical trialin Asia
    Bu, Ting
    Zhang, Pengjun
    Zang, Shiming
    Zhang, Lulu
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [8] ECONOMIC ANALYSIS OF 177LU-PSMA-I&T IN AUSTRALIAN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Ayati, Nayyereh
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 31 - 31
  • [9] Intensified therapy with 177Lu-PSMA-I&T in patients with high-volume metastatic castration-resistant prostate cancer
    Mader, Nicolai
    Haghghi, Sarvar
    Klimek, Konrad
    Schoeler, Christina
    Sarvestani, Mohammadreza Kamali
    Roedel, Claus
    Chun, Felix K. H.
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [10] Radical prostatectomy following neo-adjuvant chemo-hormonal therapy for high-risk or locally advanced prostate cancer: A phase I/II study.
    Konety, BR
    Eastham, J
    Scardino, PT
    Donat, SM
    Dalbagni, G
    Russo, P
    Herr, HW
    Scher, H
    Kelly, WK
    JOURNAL OF UROLOGY, 2002, 167 (04): : 306 - 306
12345